Please check your internet connection and try again.
# Meftal-Spas
## Overview
Meftal-Spas is a combination drug containing **Mefenamic Acid** (250 mg), a non-steroidal anti-inflammatory drug (NSAID), and **Dicyclomine Hydrochloride** (10 mg), an antispasmodic/anticholinergic agent. It is used for the relief of smooth muscle spasms and associated pain.
## Primary Indications
* Primary dysmenorrhea (menstrual cramps).
* Abdominal pain/cramps associated with gastrointestinal hypermotility.
* Spasmodic pain of the lower urinary tract.
## Adult Dosing
* **Standard dose:** 1 tablet (250mg/10mg) orally 3–4 times daily as needed.
* **Maximum dose:** Do not exceed 4 tablets in 24 hours.
* **Duration:** Limit use to the shortest duration possible, typically not exceeding 7 days due to Mefenamic Acid toxicity risks.
## Pediatric Dosing
* **Safety notice:** Not recommended for children under 12 years of age.
* **Adolescents (12+ years):** Same as adult dosing (1 tablet up to 3 times daily), but use should be minimized. Pediatric dosing varies by local protocol and weight; verify with facility guidelines before administration.
## Dose Adjustments
* **Renal Impairment:** Avoid in patients with moderate to severe renal impairment (CrCl < 30 mL/min). Use with caution in mild impairment.
* **Hepatic Impairment:** Avoid in patients with active liver disease.
* **Elderly:** Use the lowest effective dose for the shortest duration; increased risk of GI bleeding and anticholinergic side effects (e.g., urinary retention, confusion).
## Contraindications
* Known hypersensitivity to Mefenamic Acid, Dicyclomine, or aspirin/other NSAIDs.
* Active peptic ulceration or inflammatory bowel disease (IBD).
* History of GI bleeding.
* Severe renal or hepatic failure.
* Pre-operative pain management in the setting of CABG surgery.
* Obstructive uropathy, intestinal obstruction, or paralytic ileus (due to Dicyclomine).
* Third trimester of pregnancy.
## Adverse Effects
* **Mefenamic Acid related:** Dyspepsia, nausea, diarrhea, GI ulceration, increased risk of cardiovascular thrombotic events.
* **Dicyclomine related:** Dry mouth, blurred vision, tachycardia, constipation, dizziness, urinary hesitancy, and confusion.
## Key Drug Interactions
* **Anticoagulants (e.g., Warfarin):** Increased risk of bleeding.
* **Other NSAIDs/Corticosteroids:** Increased risk of GI toxicity/ulceration.
* **Anticholinergics:** Synergistic effects with Dicyclomine (e.g., increased risk of delirium or urinary retention).
* **Methotrexate/Lithium:** Mefenamic acid may increase serum concentrations and toxicity.
## Monitoring
* Monitor for signs of GI bleeding (melena, hematemesis).
* Monitor renal function (creatinine) and blood pressure.
* Monitor for signs of anticholinergic toxicity (extreme dry mouth, urinary retention, blurred vision, confusion).
## Clinical Pearls
* **Food interaction:** Take with or after food to minimize gastric irritation caused by Mefenamic Acid.
* **Drowsiness:** Dicyclomine may impair mental alertness; advise patients to avoid driving or operating machinery until the response to the drug is known.
* **Fluid intake:** Encourage adequate hydration to mitigate anticholinergic effects.
* **Withdrawal:** If symptoms persist, investigate the underlying cause of the spasms; this medication provides symptomatic relief but does not treat the etiology.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and availability can change based on regional regulations and clinical guidelines. Always consult the most current local prescribing information (package insert) or a clinical pharmacist before prescribing or administering medication.
